ID
13603
Description
Study to Assess the Safety, Tolerability, and Efficacy of Tipifarnib Plus Bortezomib in the Treatment of Acute Myeloid Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT00510939
Lien
https://clinicaltrials.gov/show/NCT00510939
Mots-clés
Versions (1)
- 19/02/2016 19/02/2016 -
Détendeur de droits
CC BY-NC 3.0
Téléchargé le
19 février 2016
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY-NC 3.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
Eligibility Acute Myeloid Leukemia NCT00510939
Eligibility Acute Myeloid Leukemia NCT00510939
- StudyEvent: Eligibility
Description
Exclusion Criteria
Alias
- UMLS CUI
- C0680251
Description
1. serum bilirubin 2 x> upper limit of normal (uln)
Type de données
boolean
Alias
- UMLS CUI [1]
- C1278039
Description
2. aspartate aminotransferase (ast/sgot) or alanine aminotransferase (alt/sgpt) >3.5 x uln
Type de données
boolean
Alias
- UMLS CUI [1]
- C0201836
- UMLS CUI [2]
- C0201899
Description
3. serum creatinine ³ 2.5 x uln or 24-hour creatinine clearance £ 60 ml/min (measured or calculated by cockcroft-gault)
Type de données
boolean
Alias
- UMLS CUI [1]
- C0201976
- UMLS CUI [2]
- C0373595
Description
4. patients with aml of fab m3 classification (apl)
Type de données
boolean
Alias
- UMLS CUI [1]
- C0023487
Description
5. patients with a history of another primary malignancy within the previous 1 year other than basal cell carcinoma or carcinoma in situ, the patient is in remission
Type de données
boolean
Alias
- UMLS CUI [1]
- C0006826
Description
6. any clinically defined central nervous system aml.
Type de données
boolean
Alias
- UMLS CUI [1]
- C1332884
- UMLS CUI [2]
- C0023467
Description
7. participation in an investigational drug study within the 30 days prior to entry
Type de données
boolean
Alias
- UMLS CUI [1]
- C2348568
Description
8. evidence of uncontrolled infection or cns-hemorrhagic
Type de données
boolean
Alias
- UMLS CUI [1]
- C0009488
Description
9. patients with documented cases of human immunodeficiency virus (hiv)
Type de données
boolean
Alias
- UMLS CUI [1]
- C0019682
Description
10. peripheral neuropathy or neuropathic pain grade > or = 2
Type de données
boolean
Alias
- UMLS CUI [1]
- C0031117
- UMLS CUI [2]
- C0458960
Description
11. has known or suspected hypersensitivity or intolerance to boron, mannitol, or heparin, if an indwelling catheter is used
Type de données
boolean
Alias
- UMLS CUI [1,1]
- C0020517
- UMLS CUI [1,2]
- C0006030
- UMLS CUI [2,1]
- C0020517
- UMLS CUI [2,2]
- C0024730
- UMLS CUI [3,1]
- C0020517
- UMLS CUI [3,2]
- C0019134
Description
12. uncontrolled or severe cardiovascular disease including myocardial infarction within 6 months of enrollment, new york heart association (nyha) class iii or iv heart failure (attachment 7,nyha classification of cardiac disease), uncontrolled angina, clinically significant pericardial disease, or cardiac amyloidosis
Type de données
boolean
Alias
- UMLS CUI [1]
- C0018799
Description
13. rasgrp1/aptx gene expression ratio calculated at the screening <10 (part b.2 only)
Type de données
boolean
Alias
- UMLS CUI [1]
- C1419283
- UMLS CUI [2]
- C1423885
Similar models
Eligibility Acute Myeloid Leukemia NCT00510939
- StudyEvent: Eligibility
C0023467 (UMLS CUI [2,1])
C1518321 (UMLS CUI [2,2])
C0392920 (UMLS CUI [3,1])
C3841806 (UMLS CUI [3,2])
C0035020 (UMLS CUI [1,2])
C0001779 (UMLS CUI [2])
C0392920 (UMLS CUI [2])
C0232970 (UMLS CUI [2])
C1423885 (UMLS CUI [2])
C0201899 (UMLS CUI [2])
C0373595 (UMLS CUI [2])
C0023467 (UMLS CUI [2])
C0458960 (UMLS CUI [2])
C0006030 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C0024730 (UMLS CUI [2,2])
C0020517 (UMLS CUI [3,1])
C0019134 (UMLS CUI [3,2])
C1423885 (UMLS CUI [2])
Aucun commentaire